July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

In December, Novo Nordisk reported that CagriSema was able to muster a 22.7% weight loss at 68 weeks in REDEFINE 1, which also fell short of its hoped-for reduction of 25%.

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Novo Nordisk shares fell due to a supply issue in the US, disappointing trial results for its new weight loss drug CagriSema, and heightened competition. The trust declared an interim dividend of 1.4p ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

The results are a boost to Novo Nordisk after another weight-loss therapy, CagriSema (cagrilintide and semaglutide), delivered lower-than-hoped-for weight loss of 20.4% at 68 weeks in a phase 3 ...

Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to ...